PPIF and nervous system disorder: The action of JW47 demonstrates that pharmacological inhibitors of the PT pore are neuroprotective in EAE, as predicted using genetic ablation studies of CypD (20) and P66ShcA in the PT pore pathway (21, 99), and may provide a treatment for neurodegeneration and progression of disability during relapsing-remitting and progressive MS and other neurological diseases.